ArticleCureus2025
Prevalence and Predictors of Metabolic Syndrome in Women with Polycystic Ovarian Syndrome: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From metabolites to membrane vesicles: Unifying gut microbial signals in obesity, t2dm, and MASLD.World journal of microbiology & biotechnology · 2026Review
- The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions.Nutrients · 2026Review
- Epidemiological Transition in Health Risks and Disease Burden Among Women of Childbearing Age in East Asia and the Pacific, 1990-2023.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age and is strongly associated with metabolic disturbances. The coexistence of PCOS and metabolic syndrome (MetS) significantly increases the risk of type 2 diabetes mellitus and cardiovascular disease. The present study aimed to determine the prevalence and predictors of MetS among women with PCOS attending a tertiary care hospital in South India.
methodsA hospital-based cross-sectional study was conducted among 70 women aged 18-45 years diagnosed with PCOS as per the Rotterdam 2003 criteria. Data on demographic, clinical, anthropometric, biochemical, and lifestyle factors were collected using a structured proforma. MetS was diagnosed based on the National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III, 2005) revised criteria with Asian-specific waist circumference cut-offs. Statistical analyses included chi-square tests, independent
resultsThe overall prevalence of MetS was 32 (45.7%) (95% CI: 33.9-57.8%). Among individual MetS components, 54 (77.1%) had elevated waist circumference, 46 (65.7%) had low HDL cholesterol, 38 (54.3%) had high triglycerides, 28 (40.0%) had elevated blood pressure, and 26 (37.1%) had elevated fasting glucose. Women aged ≥26 years 26(81.3%), obese with BMI ≥27.5 kg/m² 26 (81.3%), and centrally obese (waist ≥88 cm; 30(93.8%)) were significantly more likely to have MetS (p<0.001). Insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR) ≥2.5) was present in 30 (93.8%) women with MetS compared to 18 (47.4%) without MetS (p=0.013). Lifestyle factors such as low physical activity (26, 81.3%) and high refined-carbohydrate intake (28, 87.5%) were also strongly associated.
conclusionNearly half of women with PCOS had MetS, predominantly driven by obesity, central adiposity, and insulin resistance. Routine metabolic screening, early lifestyle modification, and integrated management are essential to prevent long-term cardiometabolic complications in this high-risk group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.